Nigel Bernard John Clerkin
Known title: Chief Financial OfficerCIK: 0002085465
Associated companies
Transaction History
| ICLR | ▼ Sell | Open Market | 237 | $39K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 1,591 | $262K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 180 | $30K | 8/11/2026 | View on chart |
| ICLR | ▼ Sell | Open Market | 259 | $42K | 8/11/2026 | View on chart |
| ICLR | ▲ Buy | Option Exercise | 918 | — | 8/10/2026 | View on chart |
| ICLR | ▲ Buy | Option Exercise | 3,375 | — | 8/10/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Icon plc (ICLR) gets new US trial boost and UBS price target update
Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.
Icon plc (ICLR) gets new US trial boost and UBS price target update. Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.